- Trials with a EudraCT protocol (355)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
355 result(s) found for: Cancer prevention.
Displaying page 1 of 18.
EudraCT Number: 2017-000131-13 | Sponsor Protocol Number: DDD17CRCCXB1 | Start Date*: 2017-05-11 |
Sponsor Name:KU Leuven | ||
Full Title: Pharmacokinetics of Celebrex for the prevention/treatment of colorectal cancer: Systemic pharmacokinetics and elimination of Celebrex in healthy volunteers | ||
Medical condition: Colorectal cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-010260-41 | Sponsor Protocol Number: IEO S462/109 | Start Date*: 2009-11-13 |
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | ||
Full Title: Breast cancer prevention with fenretinide in young women at genetic and familial risk. A phase III randomized clinical trial | ||
Medical condition: prevention in patients with high risk for breast cancer | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003115-34 | Sponsor Protocol Number: V1 | Start Date*: 2012-06-06 |
Sponsor Name:Medizinische Universität Wien | ||
Full Title: A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles after Pelvic Lymphadenectomy in Women with Gynecologic Malignancies: a Randomized Clinical Trial | ||
Medical condition: endometrial cancer, cervical cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004853-27 | Sponsor Protocol Number: Palonosetron | Start Date*: 2007-09-05 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: A phase IV monocentre study to evaluate palonosetron in nausea/vomiting prevention in patients with breast or colon cancer, treated with moderately aemotogenic chemotherapic agents | |||||||||||||
Medical condition: nausea and vomiting prevention | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002895-32 | Sponsor Protocol Number: ML21308 | Start Date*: 2007-08-29 |
Sponsor Name:Roche AB | ||
Full Title: A phase II trial assessing Metronidazol Actavis 1% topical cream in the prevention and treatment of Erlotinib associated rash | ||
Medical condition: Erlotinib associated rash | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002293-44 | Sponsor Protocol Number: PRAKYFRA-01 | Start Date*: 2018-07-25 | |||||||||||
Sponsor Name:VIFOR FRANCE | |||||||||||||
Full Title: A Pragmatic randomized study to evaluate the comparative effectiveness of Akynzeo® and Standard of care (including Emend®) for the prevention of nausea and vomiting (CINV) in cancer patients receiv... | |||||||||||||
Medical condition: prevention of nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003548-35 | Sponsor Protocol Number: MesaCAPP | Start Date*: 2017-03-10 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome | |||||||||||||
Medical condition: Colorectal Cancer Prevention in Lynch syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001194-16 | Sponsor Protocol Number: DDD17CRCP2 | Start Date*: 2017-12-11 |
Sponsor Name:KU Leuven | ||
Full Title: Pharmacokinetics of celecoxib for the prevention/treatment of colorectal cancer: optimization of intestinal sampling for celecoxib in healthy volunteers | ||
Medical condition: Colorectal cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002773-10 | Sponsor Protocol Number: IRFMN-LUNG-8287 | Start Date*: 2022-03-14 | ||||||||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | ||||||||||||||||||
Full Title: A phase III prevention trial of canakinumab in subjects at high risk for lung cancer | ||||||||||||||||||
Medical condition: Subjects at high risk for lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020943-10 | Sponsor Protocol Number: GA10/9312 | Start Date*: 2011-03-16 | |||||||||||
Sponsor Name:University of Leeds | |||||||||||||
Full Title: A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme... | |||||||||||||
Medical condition: colorectal adenoma (polyp) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001786-18 | Sponsor Protocol Number: CZOL446GDE08 | Start Date*: 2005-03-22 | |||||||||||
Sponsor Name:EAU EUROPEAN ASSOCIATION OF UROLOGY | |||||||||||||
Full Title: Effectiveness of Zometa treatment for the prevention of bone metastases in high risk prostate cancer patients. A randomized, open-label, multicenter study of the European Association of Urology (EA... | |||||||||||||
Medical condition: Prevention of bone metastasis in high risk prostate cancer patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009921-28 | Sponsor Protocol Number: PLOTINA | Start Date*: 2010-05-15 |
Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | ||
Full Title: The Effect of Metformin, an insulin-sensitizing drug, on Breast Cancer Primary Prevention: The Plotina Breast Cancer Prevention Randomized, Placebo Controlled Trial | ||
Medical condition: Breast cancer chemoprevention | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004429-25 | Sponsor Protocol Number: TS-001-DK | Start Date*: 2006-10-31 | |||||||||||
Sponsor Name:Viborg Sygehus | |||||||||||||
Full Title: A single cohort, open trial to evaluate the efficacy and safety of TachoSil in prevention of seroma formation following axillary lymph node dissection in women following surgery for breast cancer. ... | |||||||||||||
Medical condition: Seroma formation in the axilla following axillary dissection of lymphnodes following surgery for breast cancer in women | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002935-25 | Sponsor Protocol Number: 2609 | Start Date*: 2006-06-27 | |||||||||||
Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE | |||||||||||||
Full Title: multicenter phase II study to evaluate palonosetron +desametasone in the prevention of nausea and vomiting in patientes resected for colon cancer and treated with moderate emetogenus chemotherapy. | |||||||||||||
Medical condition: patientes resected for colon cancer and treated with moderate emetogenus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002119-23 | Sponsor Protocol Number: IEO1253 | Start Date*: 2020-11-16 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: COVitaminD Trial: prevention of complications from COVID-19 in cancer patients under active treatment | |||||||||||||
Medical condition: Oncological patients in active oncological treatment diagnosed with Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003036-20 | Sponsor Protocol Number: 1-2016 | Start Date*: 2017-10-02 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: A randomized trial of multifactorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program | |||||||||||||
Medical condition: health subjects (multifactorial primary prevention) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002068-27 | Sponsor Protocol Number: 500 | Start Date*: 2006-04-20 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Prevention of venous thrombosis in cancer patients: A prospective, randomized, double-blind study comparing two different dosages of low-molecular weight heparin | ||
Medical condition: cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005090-20 | Sponsor Protocol Number: FADOI.01.2016 | Start Date*: 2018-05-17 | ||||||||||||||||
Sponsor Name:FONDAZIONE FADOI | ||||||||||||||||||
Full Title: Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study. THE PRO-LAPS STUDY II | ||||||||||||||||||
Medical condition: Prevention of venous thromboembolism after laparoscopic surgery for colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002082-13 | Sponsor Protocol Number: BUF-17/RAP | Start Date*: 2008-07-09 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Randomised, double-blind, placebo-controlled, multicentre, comparative phase II pilot study on the efficacy and tolerability of an 8-week rectal treatment with 2 mg budesonide or placebo for the pr... | |||||||||||||
Medical condition: prevention of acute radiation proctitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003219-66 | Sponsor Protocol Number: | Start Date*: 2006-04-28 |
Sponsor Name:university Hospitals of Leicester NHS Trust | ||
Full Title: Allopurinol in the prevention of superficial bladder tumour recurrence | ||
Medical condition: Superficial Bladder Cancer - Role of allopurinol in prevention of tumour recurrence | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
